Gap Junction Enhancer Potentiates Cytotoxicity of Cisplatin in Breast Cancer Cells.
about
Targeting connexin 43 with α-connexin carboxyl-terminal (ACT1) peptide enhances the activity of the targeted inhibitors, tamoxifen and lapatinib, in breast cancer: clinical implication for ACT1Antiproliferative Action of Conjugated Linoleic Acid on Human MCF-7 Breast Cancer Cells Mediated by Enhancement of Gap Junctional Intercellular Communication through Inactivation of NF- κ B.Gap junctions and cancer: communicating for 50 years.The role of gap junctions in inflammatory and neoplastic disorders (Review).Genetics: Transcribing for the enemy.
P2860
Gap Junction Enhancer Potentiates Cytotoxicity of Cisplatin in Breast Cancer Cells.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Gap Junction Enhancer Potentiates Cytotoxicity of Cisplatin in Breast Cancer Cells.
@en
Gap Junction Enhancer Potentiates Cytotoxicity of Cisplatin in Breast Cancer Cells.
@nl
type
label
Gap Junction Enhancer Potentiates Cytotoxicity of Cisplatin in Breast Cancer Cells.
@en
Gap Junction Enhancer Potentiates Cytotoxicity of Cisplatin in Breast Cancer Cells.
@nl
prefLabel
Gap Junction Enhancer Potentiates Cytotoxicity of Cisplatin in Breast Cancer Cells.
@en
Gap Junction Enhancer Potentiates Cytotoxicity of Cisplatin in Breast Cancer Cells.
@nl
P2860
P1476
Gap Junction Enhancer Potentiates Cytotoxicity of Cisplatin in Breast Cancer Cells.
@en
P2093
Thu Annelise Nguyen
P2860
P304
P356
10.4172/1948-5956.1000170
P577
2012-11-01T00:00:00Z